India Ratings and Research (Ind-Ra) has retained a neutral outlook on India’s pharmaceutical sector for FY27, projecting revenue growth of around 10 percent year on year. The growth is expected to be driven by sustained domestic demand and rising momentum in the contract development and manufacturing organisation segment.
India Ratings And Research Pharma | 19/02/2026 | By Darshana
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy